A 13-week single-arm evaluation of inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes

This study evaluated glycemic outcomes in 49 adult patients with type 1 diabetes who were treated with Technosphere insulin inhalation powder plus insulin degludec. The primary outcome was non-inferiority for daytime time-in-range (70–180 mg/dL) after 13 weeks of treatment. Other study outcomes included FEV1, which was measured using the Vitalograph Asma-1 respiratory monitor.